Welcome to the Investor Relations section of the Ergomed website.


This area is dedicated to keeping shareholders and potential investors up to date with share price, news and other relevant information.

TR-1 Forms should be sent to ir@ergomedplc.com

Stock Code

ERGO

Accounting Year End

31 December

Country of Registration

England

Main Country of Operation

UK

Date Listed

15 July 2014

Index Market

AIM

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed’s fast-growing services business includes an industry leading suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, a full range of high-quality clinical research and trial management services under the Ergomed brand, and an internationally recognised specialist expertise in orphan drug development, under the PSR brand.

The Ergomed group employs over 1,000 people and operates out of 16 offices around the world, providing its services to researchers and patients in over 100 countries globally.

Pharmacovigilance

PrimeVigilance is recognised as a global leader in providing pharmacovigilance, regulatory and medical information services.  PrimeVigilance’s growth has been facilitated by our focus on a “quality first” approach, ongoing investment in people, recruitment and training, and the development and deployment of the latest available technologies, including automation and robotic technology.

PrimeVigilance’s dedicated website is at www.primevigilance.com.

Clinical Research Outsourcing (“CRO”)

Ergomed delivers high-quality CRO services through a comprehensive offering of clinical trial research support, covering all phases of medical development via a global network of research experts and patients.

Our CRO brands, Ergomed and PSR Orphan Experts, are leading providers of full-service clinical research in the specialist areas of oncology and orphan drug development. Using their extensive experience in specialist fields and their global presence, both brands are able to focus on effective patient recruitment and reducing the time and cost of clinical trials across all phases of development.

ERGOMED
The Surrey Research Park
1 Occam Court
Guildford, Surrey GU2 7HJ
United Kingdom

Board of Directors

Dr Miroslav Reljanović

Executive Chairman

Dr Miroslav Reljanović

Executive Chairman

Dr. Miroslav Reljanović is a medical doctor and a board-certified neurologist. Whilst practicing as a physician in a large WHO Collaborating Centre in Zagreb, Croatia, he was the clinical investigator in numerous Phase II and III studies in the field of neurology and a consultant to various pharmaceutical companies. Miro founded Ergomed in 1997 and introduced the novel Study Site Coordination model as an intrinsic part of the conduct of clinical studies.

Miro co-founded PrimeVigilance in 2008, that quickly became a leading specialist vendor of contracted pharmacovigilance services to the pharmaceutical industry, winning the Queen’s Award for enterprise in 2014 and again in 2019.

In July 2014 Miro led Ergomed through a successful IPO on the AIM market of the London Stock Exchange and the subsequent completion of numerous acquisitions and secondary offerings.

Miro brings to the Board his in-depth experience in clinical development and the operational execution of drug development, as well as a detailed knowledge of the Group and its operations.

Miro is Chair of Ergomed’s Nomination Committee.

Richard Barfield

Chief Financial Officer

Richard Barfield

Chief Financial Officer

Richard joined Ergomed as Chief Financial Officer in June 2019. Since qualifying as a chartered accountant, Richard has more than 25 years’ experience at Chief Financial Officer level in the healthcare, technology and business services sectors in US multinational companies as well as in UK-listed and PE-backed businesses. His expertise includes turnarounds, fundraisings, acquisitions and disposals, and he has extensive international experience. Richard has also held roles as Chief Executive Officer, Chairman, and Audit Committee Chairman of UK-listed companies as well as serving as a Board Member of an NHS Foundation Trust.
Richard has proven experience within the contract research sector, having most recently been Chief Financial Officer at Chiltern International Ltd from July 2013 to March 2018, which was a leading global mid-tier private CRO. During his five years at Chiltern, Richard was instrumental in transforming the corporate finance and strategy of the business, enabling it to grow revenues from $160m to $550m and deliver significant returns to its investors.

Rolf Soderstrom

Non-Executive Director and Senior Independent Director

Rolf Soderstrom

Non-Executive Director and Senior Independent Director

Rolf Soderstrom has over 30 years’ experience in finance and a track record of  accelerating the profitable growth of companies and delivering shareholder returns. Rolf has extensive strategic, operational and international experience including M&A, fundraisings and disposals.

During his time as CFO of BTG plc from 2008 to 2018, Rolf helped drive the successful transformation of the company into a fully integrated global manufacturing and sales organisation focused on specialist healthcare. As a key member of the leadership team he helped BTG grow from a small UK based business with 60 employees, to a global business with more than 1,500 people across North America, Asia and Europe. During this period the share price outperformed the FTSE 250 and the market capitalisation increased from approximately £400 million to £3 billion driven by a combination of organic growth and acquisitions.

Before joining BTG Rolf was Divisional Finance Director at Cobham Plc from 2004 to 2007 where he was responsible for a portfolio of 17 companies in Europe and the United States with combined turnover of £400 million. Prior to this he was Director of Corporate Finance at Cable & Wireless Plc. He qualified as a chartered accountant at PricewaterhouseCoopers where he worked initially in audit and then in the corporate finance function.

Rolf serves as Ergomed’s Senior Independent Director. He is Chair of Ergomed’s Audit and Risk Committee and a member of its Remuneration and Nomination Committees.

Michael Spiteri

Non-Executive Director

Michael Spiteri

Non-Executive Director

Michael has held a number of senior leadership positions in the consulting industry and financial services industry over a 25 year period. He specialises in helping organisations implement technology that transforms their business and operating models and is currently the Global COO for Digital, Data and Development in HSBC’s Retail Banking and Wealth Management business.

Michael was previously a partner at PwC and held senior leadership positions at Accenture and IBM. He was involved in the early stages of telematics and the development of automation technology and business models in insurance and telecoms. Michael has a degree in Mechanical Engineering and designed real time computer solutions in the oil and gas industry in the early part of his career.

Michael brings his extensive experience in technological innovation to help the Board develop Ergomed’s business across digital, automation and machine learning.

Michael is Chair of Ergomed’s Remuneration Committee, and a member of its Audit and Risk and Nomination Committees.

Ian Johnson

Non-Executive Director

Ian Johnson

Non-Executive Director

Ian has spent his business career in life science and was founder and CEO of Biotrace International PLC, which was a listed company until its sale to 3M in December 2006. Most recently Ian was Executive Chairman of Bioquell PLC, which was acquired by Ecolab Inc. in January 2019.  Prior to this Ian was non-executive Chairman of Quantum Pharma PLC, Cyprotex PLC and Celsis Group Ltd. He has also served on the boards of various other public and private companies including Aim listed companies; Evans Analytical Group, MyCelx Technologies Corporation and AOI Medical Inc.

Ian studied at Cardiff University obtaining a B.Sc. and M.Sc. in Microbiology. He is a chartered biologist, a member of the Institute of Biology and the Institute of Directors.

Ian is a member of Ergomed’s Audit and Risk Committee.

The following information is disclosed in accordance with Rule 26 of the AIM Rules for Companies.

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed’s fast-growing services business includes an industry leading suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, a full range of high-quality clinical research and trial management services under the Ergomed brand, and an internationally recognised specialist expertise in orphan drug development, under the PSR brand.

The Ergomed group employs over 1,000 people and operates out of 16 offices around the world, providing its services to researchers and patients in over 100 countries globally.

Pharmacovigilance

PrimeVigilance is recognised as a global leader in providing pharmacovigilance, regulatory and medical information services.  PrimeVigilance’s growth has been facilitated by our focus on a “quality first” approach, ongoing investment in people, recruitment and training, and the development and deployment of the latest available technologies, including automation and robotic technology.

PrimeVigilance’s dedicated website is at www.primevigilance.com.

Clinical Research Outsourcing (“CRO”)

Ergomed delivers high-quality CRO services through a comprehensive offering of clinical trial research support, covering all phases of medical development via a global network of research experts and patients.

Our CRO brands, Ergomed and PSR Orphan Experts, are leading providers of full-service clinical research in the specialist areas of oncology and orphan drug development. Using their extensive experience in specialist fields and their global presence, both brands are able to focus on effective patient recruitment and reducing the time and cost of clinical trials across all phases of development.

Audit and Risk Committee

The Audit and Risk Committee has Rolf Soderstrom as chair, and has primary responsibility for monitoring the quality of internal controls, ensuring that the financial performance of the Company is properly measured and reported on and reviewing reports from the Company’s auditors relating to the Company’s accounting and internal controls, in all cases having due regard to the interests of Ergomed’s shareholders.

The Audit and Risk Committee is also responsible for ensuring that the Company is complying with the AIM rules and its corporate governance obligations and for assessing the Company’s corporate governance practices.

The Audit and Risk Committee meets at least twice a year. Michael Spiteri and Ian Johnson are the other members of the Audit and Risk Committee.

Remuneration Committee

The Remuneration Committee has Michael Spiteri as Chair, and reviews the performance of the executive directors and determines their terms and conditions of service, including their remuneration and the grant of options, having due regard to the interests of shareholders.

The Remuneration Committee meets at least twice a year. Rolf Soderstrom is the other member of the Remuneration Committee.

Nomination Committee

The Nomination Committee has Dr. Miroslav Reljanovic as Chair, and identifies and nominates for the approval of the Board, candidates to fill board vacancies as and when they arise.

The Nomination Committee meets at least twice a year. Michael Spiteri and Rolf Soderstrom are the other members of the Nomination Committee.

Number of Ordinary Shares in issue: 48,719,526 (as at 31 January 2021)

Shareholder  Analysis (as at 31 January 2021)

Shares not in public hands (including shares held by Directors): 22.58%

Significant shareholders:

Dr. Miroslav Reljanović 22.33%
BlackRock 10.67%
Aberdeen Standard Investments 10.26%
JP Morgan Asset Management 8.41%
Jupiter Asset Management 5.49%
Slater Investments 5.43%
Octopus Investments 3.83%
Aegon Asset Management UK 3.07%

 

TR-1 Forms should be sent to ir@ergomedplc.com

In addition to the AIM market, the Company’s shares are also traded on Xetra, the electronic trading system of Deutsche Börse AG in Germany. The ISIN is GB00BN7ZCY67 and the ticker symbol is ZEMGR.

The Company is subject to the UK City Code on Takeovers and Mergers

This information is being provided for AIM Rule 26 compliance

The Board of Ergomed plc recognises the importance of sound corporate governance and has adopted the QCA Corporate Governance Code (published in April 2018 by the Quoted Companies Alliance). The QCA Corporate Governance Code states that “Companies need to deliver growth in long-term shareholder value. This requires an efficient, effective and dynamic management framework and should be accompanied by good communication which helps to promote confidence and trust”.

Ergomed’s Corporate Governance Statements, explain how Ergomed complies with the ten principles of the QCA Corporate Governance Code and are updated annually.

Ergomed’s Corporate Governance Statements are available here:

Corporate Governance Statement 2020

Corporate Governance Statement 2019

Corporate Governance Statement 2018

Nominated Adviser & Broker

Numis Securities Limited
10 Paternoster Square
London
EC4M 7LT

Solicitors to the Company

Covington & Burling LLP
265 Strand
London
WC2R 1BH

Registrars

Share Registrars Limited
The Courtyard, 17 West Street
Farnham, Surrey
GU9 7DR

Auditor

KPMG
1 Stokes Place
St. Stephen’s Green
Dublin 2
Ireland

Financial PR (UK)

Consilium Strategic Communications
41 Lothbury
London
EC2R 7HG

Financial PR (Continental Europe)

MC Services AG
Kaiser Friedrich Ring 5
40545 Dusseldorf
Germany

The following analysts currently issue reports on Ergomed. To obtain a copy of their research reports, please contact them as per the details below:

Please find below a link to Edison’s reports on Ergomed

 


Millions of people fall victim to scams every year, from experienced investors to people dealing with a large sum for the first time. They may offer to sell shares that turn out to be worthless or non-existent, or to buy shares at an inflated price in return for an upfront payment. While high profits are promised, if you buy or sell shares in this way you will probably lose your money.

‎In particular, it has come to our attention that individuals have been sent letters purporting to come from Ergomed, together with a contract note asking for payment to be made to an account in settlement of a share purchase. These are not from Ergomed and the adviser referred to in these letters, Applied Finance Group, has not been engaged by Ergomed for any purposes and you should not transfer any money to them.

Protect yourself

Investment scams are designed to look like genuine investments. You should take these steps to spot and avoid them before handing over any money:

  1. You should treat any call, email or letter with extreme caution. Get the name of the person and the organisation contacting you.
  2. Check the FCA Warning List to ensure they are authorised.
  3. Use the details on the Financial Services Register to contact the firm.
  4. Call the FCA Consumer Helpline on 0800 111 6768 if there are no contact details on the Register or you are told they are out of date.
  5. Search the list of unauthorised firms and individuals to avoid doing business with at www.fca.org.uk scams

Report a scam

If you think you have been contacted by fraudsters you should tell the FCA using the share fraud reporting form or call the FCA Consumer Helpline on 0800 111 6768.‎

If you have lost money to investment fraud, you should report it to Action Fraud on 0300 123 2040 or online at www.actionfraud.police.uk